IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10351522 B1

PDFFull Text
Date of Patent:
Jul. 16, 2019

Filed:

Jun. 10, 2016

Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof

Applicants:

University of Tsukuba, Tsukuba-shi, Ibaraki, JP;

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Hiroshi Nagase, Tsukuba, JP;

Masashi Yanagisawa, Tsukuba, JP;

Tsuyoshi Saitoh, Tsukuba, JP;

Noriki Kutsumura, Tsukuba, JP;

Yoko Irukayama, Tsukuba, JP;

Assignees:

UNIVERSITY OF TSUKUBA, Tsukuba, JP;

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US);

Attorney:

Leydig, Voit & Mayer, Ltd.

Primary Examiner:

Alexander R Pagano

Int. Cl.
CPC ...
C07D 213/81 (2006.01); C07C 311/29 (2006.01); A61K 31/18 (2006.01); A61K 31/341 (2006.01); A61K 31/36 (2006.01); A61K 31/381 (2006.01); A61K 31/4164 (2006.01); A61K 31/4402 (2006.01); A61K 31/4406 (2006.01); A61K 31/4409 (2006.01); A61K 31/4439 (2006.01); C07D 213/75 (2006.01); C07D 317/68 (2006.01); C07D 333/36 (2006.01); C07C 311/21 (2006.01); C07D 417/04 (2006.01); C07D 295/10 (2006.01); C07D 213/36 (2006.01); C07D 307/54 (2006.01); A61P 25/00 (2006.01); C07D 233/36 (2006.01); C07D 239/10 (2006.01); C07C 317/44 (2006.01); C07D 243/04 (2006.01); C07C 335/20 (2006.01); A61P 43/00 (2006.01);
U.S. Cl.
CPC ...
C07C 311/29 (2013.01); A61K 31/18 (2013.01); A61K 31/341 (2013.01); A61K 31/36 (2013.01); A61K 31/381 (2013.01); A61K 31/4164 (2013.01); A61K 31/4402 (2013.01); A61K 31/4406 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61P 25/00 (2018.01); A61P 43/00 (2018.01); C07C 311/21 (2013.01); C07C 317/44 (2013.01); C07C 335/20 (2013.01); C07D 213/36 (2013.01); C07D 213/75 (2013.01); C07D 213/81 (2013.01); C07D 233/36 (2013.01); C07D 239/10 (2013.01); C07D 243/04 (2013.01); C07D 295/10 (2013.01); C07D 307/54 (2013.01); C07D 317/68 (2013.01); C07D 333/36 (2013.01); C07D 417/04 (2013.01); C07C 2601/04 (2017.05);
Abstract

The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

Find Patent Forward Citations

Loading…